91575-58-5
Chemical Structure
Carbamyl-PAF
Synonym(s): C-PAF
- CAS No.: 91575-58-5
- Formula:C26H55N2O7P
- Molecular Weight:538.70
IUPAC Name: (R)-3-(hexadecyloxy)-2-((methylcarbamoyl)oxy)propyl (2-(trimethylammonio)ethyl) phosphate
InChIKey: FNFHZBKBDFRYHS-RUZDIDTESA-N
SMILES: CNC(O[C@H](COCCCCCCCCCCCCCCCC)COP(OCC[N+](C)(C)C)([O-])=O)=O
Biological Activity: Carbamyl-PAF (C-PAF) is a metabolically stable platelet-activating factor analog and PAF receptor agonist that activates G protein-coupled PAF receptors, triggering calcium mobilization, NF-κB activation, and downstream signaling, thereby inducing neutrophil recruitment, inflammatory responses, and ROS generation. Carbamyl-PAF is used in research on obesity, pulmonary inflammation, Zellweger syndrome, and non-melanoma skin cancer[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carbamyl-PAF | 99.6% | Carbamyl-PAF (C-PAF) is a metabolically stable platelet-activating factor analog and PAF receptor agonist that activates G protein-coupled PAF receptors, triggering calcium mobilization, NF-κB activation, and downstream signaling, thereby inducing neutrophil recruitment, inflammatory responses, and ROS generation. Carbamyl-PAF is used in research on obesity, pulmonary inflammation, Zellweger syndrome, and non-melanoma skin cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Goda Y. Long-Term Potentiation: In pursuit of a retrograde messenger. Current Biology. 1994 Feb 1;4(2):148-50.
- [2]. Yamaguchi M, et al. A platelet-activating factor (PAF) receptor deficiency exacerbates diet-induced obesity but PAF/PAF receptor signaling does not contribute to the development of obesity-induced chronic inflammation. Biochemical pharmacology. 2015 Feb 15;93(4):482-95.
- [3]. Silva IS, et al. Platelet-activating factor and protease-activated receptor 2 cooperate to promote neutrophil recruitment and lung inflammation through nuclear factor-kappa B transactivation. Scientific reports. 2023 Dec 07;13(1):21637.
- [4]. Dalmaso B, et al. Platelet-Activating Factor Receptor (PAFR) Regulates Retinal Progenitor/Stem Cells Profile in Ciliary Epithelium Cells. International journal of molecular sciences. 2024 Mar 07;25(6):3084.
- [5]. Shimada A, et al. In situ expression of platelet-activating factor (PAF)-receptor gene in rat skin and effects of PAF on proliferation and differentiation of cultured human keratinocytes. The Journal of investigative dermatology. 1998 Jun;110(6):889-93.
- [6]. Doublier S, et al. The proangiogenic phenotype of tumor-derived endothelial cells is reverted by the overexpression of platelet-activating factor acetylhydrolase. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Oct 01;13(19):5710-8.
- [7]. Gressens P, et al. Neuronal migration disorder in Zellweger mice is secondary to glutamate receptor dysfunction. Annals of neurology. 2000 Sep;48(3):336-43.
- [8]. Sreevidya CS, et al. Agents that reverse UV-Induced immune suppression and photocarcinogenesis affect DNA repair. The Journal of investigative dermatology. 2010 May;130(5):1428-37. [Content Brief]
- [9]. Fukuda AI, et al. Effect of platelet activating factor on embryonic development and implantation in the mouse. Human reproduction (Oxford, England). 1996 Dec;11(12):2746-9.
